Obstetric Outcomes Following Vitrification of in Vitro and in Vivo Matured Oocytes
Overview
Authors
Affiliations
Objective: To evaluate obstetric outcomes with oocyte vitrification after ovarian stimulation (OS) and in vitro maturation (IVM) of immature oocytes.
Design: A prospective trial from October 2003 to April 2007.
Setting: University-based medical center.
Patient(s): OS group: 38 patients undergoing intrauterine insemination who overresponded to OS. IVM group: 20 patients who had previous unsuccessful intrauterine insemination.
Intervention(s): Mature oocyte retrieval following OS. Immature oocyte retrieval and IVM. Oocyte vitrification, thawing, insemination, and transfer of the resulting embryos.
Main Outcome Measure(s): Live-birth rates and obstetric outcomes.
Result(s): The OS group was superior to the IVM group in terms of oocyte survival (81.4 +/- 22.6% vs. 67.5 +/- 26.1%), fertilization rate (75.6 +/- 22.5% vs. 64.2 +/- 19.9%), and cumulative embryo score (38.4 +/- 22.3 vs. 20.0 +/- 13.8). However, the differences in the implantation rate per embryo (19.1 +/- 25.8% vs. 9.6 +/- 24.1%), clinical pregnancy rate per cycle started (44.7%, vs. 20.0%), and live-birth rate per cycle started (39.5% vs. 20.0%) were not statistically significant. Twenty healthy babies were born in the OS group and four in the IVM group.
Conclusion(s): Pregnancies achieved with vitrification of oocytes after OS and IVM treatments do not appear to be associated with adverse pregnancy outcomes. Vitrification of IVM oocytes represents a novel option for fertility preservation.
Live birth after vitrification of oocytes from capacitation in vitro maturation.
Le X, Nguyen D, Nguyen T, Le T, Vuong L, Ho T J Assist Reprod Genet. 2024; 41(8):1985-1989.
PMID: 38990423 PMC: 11339008. DOI: 10.1007/s10815-024-03200-y.
Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases.
Saito S, Yamada M, Yano R, Takahashi K, Ebara A, Sakanaka H J Ovarian Res. 2023; 16(1):159.
PMID: 37563616 PMC: 10416401. DOI: 10.1186/s13048-023-01250-x.
IVM of human immature oocytes for infertility treatment and fertility preservation.
Chian R, Li J, Lim J, Yoshida H Reprod Med Biol. 2023; 22(1):e12524.
PMID: 37441160 PMC: 10335168. DOI: 10.1002/rmb2.12524.
Fertility preservation strategies for cancerous women: An updated review.
Anbari F, Khalili M, Mahaldashtian M, Ahmadi A, Palmerini M Turk J Obstet Gynecol. 2022; 19(2):152-161.
PMID: 35770454 PMC: 9249358. DOI: 10.4274/tjod.galenos.2022.42272.
Badeghiesh A, Konci R, Aldhaheri S, Son W, Dahan M J Turk Ger Gynecol Assoc. 2021; 22(3):168-173.
PMID: 34109775 PMC: 8420741. DOI: 10.4274/jtgga.galenos.2021.2020.0207.